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Ovarian cancer is the second most common of female reproductive cancer in the world, more 
women die from ovarian cancer than from cervical cancer and uterine cancer combined.1  The role of 
screening in cervical cancer is prominent, but not in ovarian cancer. Currently, there is no strategy for 
early detection of ovarian cancer that reduces ovarian cancer mortality.
      However, some effort should be done, to have better survival in the management of ovarian cancer, 
from taking a detailed family history for breast, gynecologic, and colon cancer facilitates categorizing 
women based on average high risk of developing ovarian cancer. Women with a strong family history 
of ovarian, breast, or colon cancer may have hereditary breast and ovarian cancer syndrome (BRCA 
mutation) or hereditary nonpolyposis colorectal cancer (Lynch syndrome).2 Ideally, women with these 
conditions should be offered for genetic counselling and additional testing for early detection of 
ovarian cancer. The use of transvaginal ultrasonography and tumour markers such as  Ca 125 for the 
early detection of ovarian cancer have a role but have not been proved to reduce mortality.3
The new classifi cation of histopathological based on molecular, and genetic studies have recently 
provided a better model for ovarian carcinogenesis, which are designated as Type I tumours include 
low grade serous, mucinous, endometrioid, clear cell, and transitional cell carcinomas, while type II 
tumours comprise high-grade serous carcinomas, undifferentiated carcinomas, and carcinosarcomas.4
It is very important to predict whether the adnexa tumour is malignant, borderline or benign pra 
operatively. Some scoring was implemented to predict the risk of malignancy of the adnexa tumour. 
We can use RMI (Risk Malignancy Index), Gatot Score, ROMA (Risk of Malignancy Algorithm), IOTA 
(International Ovarian Tumor Analysis).5,6 and also another scoring. We can have the application for that 
scoring formula.
Standard treatment for ovarian cancer involves aggressive debulking surgery and chemotherapy. 
Cytoreductive surgery aims to confi rm the diagnosis, defi ne the extent of disease, resect all visible 
tumour with the goal is zero residual tumours. Surgery in a case with early-stage can be done by Ob-
Gyn, with an understanding of the principles of surgery in ovarian cancer, including understanding 
the role of frozen section. But in advance stage, ideally managed by a team approach, consist of a 
gynaecologist, digestive surgeon, some times with the urology surgeon. Neoadjuvant chemotherapy is 
increasingly used.7 How to achieve better survival for ovarian cancer is challenging.
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